Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432716 · ClinicalTrials.gov registry record · Phase 1
Investigation of the Safety of Intranasal Glulisine in Down Syndrome
A Phase 1 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02432716 is a Phase 1 study that has completed, run by HealthPartners Institute. The registered enrollment target is 12 participants.
The verdict
NCT02432716, a Phase 1 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo in patients with DS. Subjects will be randomized into this cross-over study and within subject comparisons conducted between single treatment of intranasal insulin glulisine and single treatment of intranasal placebo. All subjects will also receive a single treatment of placebo prior to randomization to ensure adherence to study procedures.
Interventions
- DRUG Saline
- DRUG Insulin glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02432716
The ClinicalTrials.gov registry entry for NCT02432716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02432716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02432716 about?
NCT02432716 is a clinical study titled "Investigation of the Safety of Intranasal Glulisine in Down Syndrome". This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo in patients with DS. Subjects will be randomized into this cross-over study and within subject comparisons conduct...
What is the current status of trial NCT02432716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-04. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT02432716?
The interventions under investigation include: Saline (DRUG), Insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT02432716?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.